Payment overview · 2025
General Payments
$94.06
6 reported records · 5 companies
Healthcare provider profile · identity verified
William Joseph Kopp, MD
Allopathic & Osteopathic Physicians|Family Medicine · ANDERSON, IN · NPI 1285604371
Verified facts
What the public records show
CMS Open Payments records show William Joseph Kopp, MD received $94.06 in general payments during 2025 across 6 reported records.
PFIZER INC. accounted for 31.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.81 | 31.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.15 | 20.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.74 | 16.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.65 | 16.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.71 | 14.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $94.06 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.81 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.81 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.81 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 530 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 412 | 107 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 317 | 44 |
| Lisinopril | Lisinopril | 282 | 76 |
| Gabapentin | Gabapentin | 258 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 243 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 240 | 55 |
| Omeprazole | Omeprazole | 199 | 48 |
| Jardiance | Empagliflozin | 198 | 36 |
| Metformin Hcl | Metformin Hcl | 194 | 54 |
| Simvastatin | Simvastatin | 189 | 49 |
| Furosemide | Furosemide | 169 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 42 |
| Losartan Potassium | Losartan Potassium | 142 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 32 |
| Indapamide | Indapamide | 130 | 35 |
| Eliquis | Apixaban | 128 | 31 |
| Valsartan | Valsartan | 128 | 34 |
| Prednisone | Prednisone | 127 | 83 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 126 | 36 |
| Meloxicam | Meloxicam | 125 | 31 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 118 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 116 | 28 |
| Donepezil Hcl | Donepezil Hcl | 110 | 30 |
| Mirtazapine | Mirtazapine | 100 | 27 |
| Azithromycin | Azithromycin | 99 | 77 |
| Allopurinol | Allopurinol | 98 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 27 |
| Montelukast Sodium | Montelukast Sodium | 96 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 23 |
| Clonazepam | Clonazepam | 91 | 13 |
| Ibuprofen | Ibuprofen | 87 | 14 |
| Tramadol Hcl | Tramadol Hcl | 82 | 15 |
| Pregabalin | Pregabalin | 81 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 80 | 67 |
| Potassium Chloride | Potassium Chloride | 80 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 29 |
| Mounjaro | Tirzepatide | 77 | 17 |
| Trazodone Hcl | Trazodone Hcl | 72 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 72 | 19 |
| Buprenorphine Hcl | Buprenorphine Hcl | 71 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 69 | 15 |
| Spironolactone | Spironolactone | 63 | 17 |
| Lorazepam | Lorazepam | 61 | 17 |
| Fenofibrate | Fenofibrate | 59 | 15 |
| Carvedilol | Carvedilol | 58 | 16 |
| Farxiga | Dapagliflozin Propanediol | 58 | 20 |
| Ozempic | Semaglutide | 57 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 21 |
| Bupropion Xl | Bupropion Hcl | 53 | suppressed |
| Trulicity | Dulaglutide | 51 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 50 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 15 |
| Fluconazole | Fluconazole | 46 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 13 |
| Linzess | Linaclotide | 43 | 12 |
| Alendronate Sodium | Alendronate Sodium | 42 | 13 |
| Alprazolam | Alprazolam | 42 | suppressed |
| Aripiprazole | Aripiprazole | 42 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Naproxen | Naproxen | 40 | suppressed |
| Cefdinir | Cefdinir | 39 | 31 |
| Cephalexin | Cephalexin | 39 | 28 |
| Temazepam | Temazepam | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 36 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 22 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 24 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 17 |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | 13 |
| Famotidine | Famotidine | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $94.06 · 6 records | PFIZER INC. | ABRYSVO, Auvelity, COMIRNATY, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, UBRELVY, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error